Optimer® binders are simplifying hot start inhibition for KOD DNA Polymerase When it comes to high-fidelity PCR, few enzymes match KOD DNA Polymerase for speed and accuracy. Capable of extending…
Cancer remains a mammoth challenge, accounting for one in every six deaths globally. But aptamers are offering new solutions from reagents to next-gen ADCs. Despite the scale of the…
April 25th is DNA Day and we’re celebrating DNA aptamers and the innovation they are bringing from new medicines to new life science reagents. This day was set up…
Affinity binders are the workhorses of assays and methods across the life sciences. From biologics to bioprocessing ligands and research reagents, the requirements for affinity binders vary according to…
Protein-protein interactions were once considered undruggable. Our tailored aptamer selection approach is proving this isn’t so. Targets such as transcription factors, immune checkpoints in oncology, infectious disease agents, and…
Not all protein-binding aptamers are developed equally. And they shouldn’t be. When developing aptamers to protein targets the ‘how’ is just as important as the ‘what’. The ‘what’ is what…
Dr Daniel Wiseman is a Senior Clinical Lecturer at the University of Manchester, and a Consultant Haematologist at the Christie NHS Foundation. He is exploring Optimer® binders as…
The advent of oligonucleotide therapeutics has given rise to novel drug development strategies. Oligonucleotide ligands can operate as both independent therapeutic modalities and as delivery vehicles for diverse payloads…
Currently, prostate-specific antigen (PSA) is considered to be the most sensitive marker available for prostate cancer detection and for monitoring of disease progression. In addition to its importance as…
The prophylactic use of topical antiviral agents has recently been validated by the reduction in human immunodeficiency virus (HIV) type 1 infection incidence seen using tonofovir-containing microbicides. In order…
